Genetic polymorphisms in drug metabolism

It has now been established that genetic polymorphisms in drug metabolizing enzymes such as the cytochrome P450s (CYP) and the phase II enzyme, thiopu-rine methyltransferase, are responsible for inter-individual variability in response and adverse reactions [12, 13]. However, at the present time, the impact of poly-... 

Table 4-4 Some Examples of Genetic Polymorphisms in Drug Metabolism. ...

Alvan G. Clinical consequences of polymorphic drug oxidation. Fund Clin Pharmacol 1991 5 209. Alvan G. Genetic polymorphisms in drug metabolism. J Internal Med 1992 231 571. 

Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994 46(suppl 1) 417. 

Genetic polymorphism in drug metabolism. The graph shows the distribution of plasma concentrations of isoniazid in 267 individuals 6 hours after an oral dose of 9.8 mg/kg. This distribution is clearly bimodal. Individuals with a plasma concentration greater than 2.5 mg/mL at 6 hours are considered slow acetylators. (Redrawn, with permission, from Evans DAP, Manley KA, McKusick VA Genetic control of isoniazid metabolism in man. Br Med J 1960 2 485.)... 

A number of examples of genetic polymorphisms in drug metabolism have now been identified, involving oxidation, S-methylation, and acetylation., as shown in Table 4. These polymorphisms were initially identified by adverse drug reactions occurring in distinct... 

Breimer, D.D. (1994). Genetic polymorphisms in drug metabolism clinical implications and consequences in ADME studies. In S. Walker, C. Lumley, and N. McAuslane (eds), The Relevance of Ethnic... 

Genotypic variants occur with regard to the metabolism of isoniazid. What other drugs exhibit such variation, and what enzymes are involved in their metabolism What are the clinical consequences of genetic polymorphisms in drug metabolism The Skill Keeper Answer appears at the end of the chapter. 

---